Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Average. Abbott Laboratories scores higher than 54% of the 2,231 companies Ryufin scores.
Carried by capital allocation and cycle position, held back by return on new capital.
Healthcare median 19 · all companies 55
The biggest move was up 10 points from 2021 to 2022, mostly capital allocation.
26% of the score
Abbott Laboratories is valued at 26.4x its operating profit before acquisition amortisation (EBITA), including debt: a rich multiple.
18% of the score
Over 7 years the business earned 11% a year after tax on the capital it uses.
16% of the score
For every dollar of operating profit earned over 6 years, yearly profit grew by 1 cents. New capital earned 5.1%, and 29% of profit went back into the business.
14% of the score
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
12% of the score
Today's operating margin of 16% is 0.94x its normal 17%: close to its usual level. Normal is half the 10 year median, half the last four years, so a margin that has held is not taken for a peak.
8% of the score
What the debt weighs against the profit that has to carry it.
6% of the score
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. Where a criterion cannot be measured from the filings it is taken out and the remaining weights scale up; a company needs 60% of the weight covered, and always a price, to get a score.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
The closest names by size in the same industry